Q1 FY27: profit up 38%, EBITDA margin expands to 9.99%
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma's Q1 FY27 revenue grew 4% YoY to Rs. 193.81 Cr while profit metrics surged: EBITDA up 42% to Rs. 19.36 Cr (margin 9.99% vs 7.34%), PAT up 38% to Rs. 11.42 Cr at 5.89% margin. EPS at Rs. 1.14. Production rose 19% to 491 MT. Export share climbed to about 55% from 37% YoY. Management credits richer product mix in regulated markets (USFDA and EU GMP approved), cost discipline, and improved throughput. Company remains debt-free with ROCE at 19.18%.
Sharp profit growth far ahead of revenue signals margin-led upside. Debt-free balance sheet, 19% ROCE and intact dividends reinforce a positive setup for shareholders.